

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Tsunetoshi Honma et al.

Title: A PHARMACEUTICAL COMPOSITION COMPRISING A DUAL
ANTAGONIST AGAINST PGD₂/TXA₂ RECEPTORS HAVING A [2.2.1] OR
[3.1.1] BICYCLIC SKELETON

Appl. No.: To Be Assigned

Filing Date: September 10, 2001

Examiner: Unassigned

Art Unit: Unassigned

INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §1.56

Commissioner for Patents
Box PATENT APPLICATION
Washington, D.C. 20231

Sir:

Submitted herewith on Form PTO-1449 is a listing of documents known to Applicants in order to comply with Applicants' duty of disclosure pursuant to 37 CFR §1.56. A copy of each listed document is being submitted to comply with the provisions of 37 CFR §1.97 and §1.98.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in 37 CFR §1.56(b). Applicants do not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* art reference against the claims of the present application.

TIMING OF THE DISCLOSURE

The listed documents are being submitted in compliance with 37 CFR §1.97(b), within three (3) months of the filing date of the application.

09/936161

Atty. Dkt. No. 067242-0152

RELEVANCE OF EACH DOCUMENT

In order to comply with Applicants' duty of disclosure pursuant to 37 C.F.R. §1.56, submitted herewith on Form PTO-1449 is a listing of documents cited in the International Search Report of Applicants' International Application No. PCT/JP00/01223. A copy of the International Search Report setting forth the portion of each reference considered relevant by the Examiner is attached.

Copies of the documents are not being provided since copies should have been provided directly by WIPO under an exchange program between the PTO, the EPO and the JPO.

Applicants respectfully request that any listed documents be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO-1449 be returned in accordance with MPEP §609.

The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 C.F.R. §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 19-0741. Should no proper payment be enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 19-0741.

Respectfully submitted,

Date September 10, 2001

FOLEY & LARDNER
Washington Harbour
3000 K Street, N.W., Suite 500
Washington, D.C. 20007-5109
Telephone: (202) 672-5569
Facsimile: (202) 672-5399

By



Reg. No.
38,819

for/

Stephen B. Maebius
Attorney for Applicant
Registration No. 35,264

Form PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 067242-0152	SERIAL NO. To Be Assigned
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)		APPLICANT Tsunetoshi Honma et al.	
		FILING DATE September 10, 2001	GROUP ART UNIT Unassigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

	REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION	
							YES	NO
	A1	97/00853	01/09/1997	WIPO				
	A2	99/15502	04/01/1999	WIPO				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

		TATSUO Tsuru et al., "Bicycle [2.2.1] heptane and 6,6-Dimethylobicyclo [3.1.1] heptane Derivatives: Orally Active, Potent, and Selective Prostaglandin D2 Receptor Antagonists", <u>J. Med. Chem.</u> , Vol. 40, No. 22, pages 3504 to 3507, (1997)

EXAMINER	DATE CONSIDERED
----------	-----------------

* EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include any copy of this form with next communication to applicant.